Teladoc Health (TDOC) has narrowed its 2025 guidance ranges for both EPS and revenue.
The telehealth company now sees net loss per share for the year of ($1.25)-($1.10), from ($1.35)-($1.00) prior. Consensus is ($1.16). Revenue is now projected at $2.51B-$2.53B from $2.501B-$2.548B before. Consensus is $2.52B.
In Q3, Teladoc missed on the bottom line, while the top line was in line.
On a GAAP basis, net loss widened 47% year over year to ($0.28). Revenue declined ~2% to ~$626.4M. The integrated care segment had revenue of $389.5M, a 2% year-over-year increase.
Q3 results also included included a non-cash goodwill impairment charge of $12.6M or $0.07 per share pre-tax; stock-based compensation expense of $17.0M, or $0.10 per share pre-tax; and amortization of intangibles of $85.8M, or $0.48 per share pre-tax.
Teladoc ended the quarter (Sept. 30) with cash and cash equivalents of ~$726.2M compared to ~$1.2B in the year-ago period.
